A recent study presented at the 2018 Genitourinary Cancer Symposium in San Francisco in February reports that surgery to remove the affected kidney (cytoreductive nephrectomy) from patients with metastatic papillary renal cell carcinoma (pRCC) may improve overall survival.

Of 353 patients with metastatic pRCC, 244 patients underwent cytoreductive nephrectomy and had significantly longer median overall survival compared with the 109 patients who did not (16.3 vs 8.6 months). Risk of death was 38% lower for patients who had cytoreductive nephrectomy.

Read more in Renal & Urology News here